CL:0002320

Name:	connective tissue cell
Namespace:	FANTOM
Definition:	"A cell of the supporting or framework tissue of the body, arising chiefly from the embryonic mesoderm and including adipose tissue, cartilage, and bone." [GOC:tfm, ISBN:0618947256]
Xrefs:	Expandlinks: FMA:63875
Alt_id:	CL:1000406
Created by:	tmeehan
Creation date:	2010-09-15T03:01:54Z

Ontology association <br>Each term has an is_a parent in the Cell ontology, which has a linkage to an another entity and FANTOM5 samples.Libraries were grouped into mutually exclusive facets according to the FANTOM5 sample ontology mapping to Cell ontologies.<br><br>link to ontology dataset<br>data

---

Parents

is_a:	CL:0000548(animal cell),CL:0002371(somatic cell)
part_of:	UBERON:0002384(connective tissue)

Children

is a:	CL:0000057 (fibroblast),CL:0000058 (chondroblast),CL:0000062 (osteoblast),CL:0000134 (mesenchymal cell),CL:0000136 (fat cell),CL:0000137 (osteocyte),CL:0000499 (stromal cell),CL:0000669 (pericyte cell),CL:0002503 (adventitial cell),CL:0002564 (nucleus pulposus cell of intervertebral disc),CL:0002576 (perineural cell),CL:0002602 (annulus pulposus cell),CL:1000500 (kidney interstitial cell)

Ontology Tree: Loaded from BioPortal

Ontorolgy tree(Small window open)

FF samples<br>It includes FANTOM5 samples that overlay the Cell ontology.

---

Human (Homo sapiens)

• 10410-106B5 (extraskeletal myxoid chondrosarcoma cell line:H-EMC-SS)
• 10441-106E9 (synovial sarcoma cell line:HS-SY-II)
• 10445-106F4
• 10446-106F5
• 10447-106F6
• 10448-106F7 (endometrial stromal sarcoma cell line:OMC-9)
• 10474-106I6 (myeloma cell line:PCM6)
• 10479-107A2
• 10497-107C2 (endometrial carcinoma cell line:OMC-2)
• 10510-107D6 (osteosarcoma cell line:143B/TK^(-)neo^(R))

... further results Mouse (Mus musculus)

• 10410-106B5 (extraskeletal myxoid chondrosarcoma cell line:H-EMC-SS)
• 10441-106E9 (synovial sarcoma cell line:HS-SY-II)
• 10445-106F4
• 10446-106F5
• 10447-106F6
• 10448-106F7 (endometrial stromal sarcoma cell line:OMC-9)
• 10474-106I6 (myeloma cell line:PCM6)
• 10479-107A2
• 10497-107C2 (endometrial carcinoma cell line:OMC-2)
• 10510-107D6 (osteosarcoma cell line:143B/TK^(-)neo^(R))

... further results

Enrichment analysis: top 100 FFCP enriched with this ontology termTOP 100 FANTOM5 Cage Peaks enriched with CL:0002320 (connective tissue cell), sorted by p-values <br>Analyst: Hideya Kawaji<br><br>link to source dataset <br>human : data <br>mouse : data

---

Copy Excel CSV PDF

Search:

P-value	FFCP	Short description

P-value	FFCP	Short description
4.98e-45	FFCP PHASE2:Hg19::chr2:74781828..74781898,+	p1@DOK1
4.98e-45	FFCP PHASE1:Hg19::chr2:74781828..74781898,+	p1@DOK1
5.83e-45	FFCP PHASE2:Hg19::chr19:48828606..48828637,+	p2@EMP3
5.83e-45	FFCP PHASE1:Hg19::chr19:48828606..48828637,+	p2@EMP3
1.32e-44	FFCP PHASE1:Hg19::chr18:18691563..18691610,-	p4@ROCK1
1.32e-44	FFCP PHASE2:Hg19::chr18:18691563..18691610,-	p4@ROCK1
1.65e-44	FFCP PHASE1:Hg19::chr2:182322231..182322262,+	p2@ITGA4
1.65e-44	FFCP PHASE2:Hg19::chr2:182322231..182322262,+	p2@ITGA4
3.0e-40	FFCP PHASE2:Hg19::chr6:31704075..31704106,-	p2@CLIC1
3.0e-40	FFCP PHASE1:Hg19::chr6:31704075..31704106,-	p2@CLIC1
8.81e-40	FFCP PHASE2:Hg19::chr5:78281092..78281154,-	p1@ARSB
8.81e-40	FFCP PHASE1:Hg19::chr5:78281092..78281154,-	p1@ARSB
2.65e-39	FFCP PHASE1:Hg19::chr16:50300440..50300485,+	p1@ADCY7
2.65e-39	FFCP PHASE2:Hg19::chr16:50300440..50300485,+	p1@ADCY7
1.03e-37	FFCP PHASE1:Hg19::chr1:153518270..153518290,-	p1@S100A4
1.03e-37	FFCP PHASE2:Hg19::chr1:153518270..153518290,-	p1@S100A4
2.57e-37	FFCP PHASE2:Hg19::chr15:73076030..73076121,-	p1@ADPGK
2.57e-37	FFCP PHASE1:Hg19::chr15:73076030..73076121,-	p1@ADPGK
2.86e-36	FFCP PHASE2:Mm9::chr7:26474167..26474188,-	p@chr7:26474167..26474188, -
2.86e-36	FFCP PHASE1:Mm9::chr7:26474167..26474188,-	p@chr7:26474167..26474188, -
3.34e-36	FFCP PHASE1:Hg19::chr19:48828647..48828658,+	p3@EMP3
3.34e-36	FFCP PHASE2:Hg19::chr19:48828647..48828658,+	p3@EMP3
6.92e-36	FFCP PHASE2:Hg19::chr2:182322070..182322155,+	p1@ITGA4
6.92e-36	FFCP PHASE1:Hg19::chr2:182322070..182322155,+	p1@ITGA4
8.31e-36	FFCP PHASE2:Hg19::chr12:44152740..44152815,+	p1@IRAK4
8.31e-36	FFCP PHASE1:Hg19::chr12:44152740..44152815,+	p1@IRAK4
3.07e-35	FFCP PHASE2:Hg19::chrX:117629766..117629846,+	p1@DOCK11
3.07e-35	FFCP PHASE1:Hg19::chrX:117629766..117629846,+	p1@DOCK11
4.38e-35	FFCP PHASE2:Hg19::chr1:145096480..145096513,+	p2@SEC22B
4.38e-35	FFCP PHASE1:Hg19::chr1:145096480..145096513,+	p2@SEC22B
5.5e-35	FFCP PHASE2:Hg19::chr2:197036289..197036314,-	p1@STK17B
5.5e-35	FFCP PHASE1:Hg19::chr2:197036289..197036314,-	p1@STK17B
5.64e-35	FFCP PHASE2:Hg19::chr13:41635029..41635044,-	p4@ELF1
5.64e-35	FFCP PHASE1:Hg19::chr13:41635029..41635044,-	p4@ELF1
5.89e-35	FFCP PHASE2:Hg19::chr12:123920991..123921047,-	p1@RILPL2
5.89e-35	FFCP PHASE1:Hg19::chr12:123920991..123921047,-	p1@RILPL2
6.88e-35	FFCP PHASE1:Hg19::chr2:114647617..114647739,+	p1@ACTR3
6.88e-35	FFCP PHASE2:Hg19::chr2:114647617..114647739,+	p1@ACTR3
1.15e-33	FFCP PHASE2:Hg19::chr3:50378235..50378286,-	p2@RASSF1
1.15e-33	FFCP PHASE1:Hg19::chr3:50378235..50378286,-	p2@RASSF1
2.75e-33	FFCP PHASE2:Hg19::chr2:197036269..197036287,-	p2@STK17B
2.75e-33	FFCP PHASE1:Hg19::chr2:197036269..197036287,-	p2@STK17B
4.06e-33	FFCP PHASE2:Hg19::chr10:26727647..26727722,+	p2@APBB1IP
4.06e-33	FFCP PHASE1:Hg19::chr10:26727647..26727722,+	p2@APBB1IP
5.24e-33	FFCP PHASE2:Mm9::chr4:140255879..140255890,+	p@chr4:140255879..140255890, +
5.24e-33	FFCP PHASE1:Mm9::chr4:140255879..140255890,+	p@chr4:140255879..140255890, +
5.55e-33	FFCP PHASE1:Hg19::chr3:5229382..5229408,+	p1@EDEM1
5.55e-33	FFCP PHASE2:Hg19::chr3:5229382..5229408,+	p1@EDEM1
7.3e-33	FFCP PHASE1:Hg19::chr17:56415424..56415454,-	p@chr17:56415424..56415454, -
7.3e-33	FFCP PHASE2:Hg19::chr17:56415424..56415454,-	p@chr17:56415424..56415454, -
8.6e-33	FFCP PHASE2:Hg19::chr10:18948026..18948051,-	p1@BC033534
8.6e-33	FFCP PHASE1:Hg19::chr10:18948026..18948051,-	p1@BC033534
1.5e-32	FFCP PHASE1:Hg19::chr2:68592394..68592405,+	p2@PLEK
1.5e-32	FFCP PHASE2:Hg19::chr2:68592394..68592405,+	p2@PLEK
2.85e-32	FFCP PHASE1:Hg19::chr13:41593405..41593416,-	p9@ELF1
2.85e-32	FFCP PHASE2:Hg19::chr13:41593405..41593416,-	p9@ELF1
3.28e-32	FFCP PHASE1:Hg19::chr19:48828539..48828550,+	p4@EMP3
3.28e-32	FFCP PHASE2:Hg19::chr19:48828539..48828550,+	p4@EMP3
1.22e-31	FFCP PHASE2:Hg19::chr8:121824235..121824275,-	p1@SNTB1
1.22e-31	FFCP PHASE1:Hg19::chr8:121824235..121824275,-	p1@SNTB1
1.62e-31	FFCP PHASE1:Hg19::chr14:95982953..95982999,-	p@chr14:95982953..95982999, -
1.62e-31	FFCP PHASE2:Hg19::chr14:95982953..95982999,-	p@chr14:95982953..95982999, -
1.76e-31	FFCP PHASE1:Mm9::chr1:175560978..175561013,+	p1@Pyhin1
1.76e-31	FFCP PHASE2:Mm9::chr1:175560978..175561013,+	p1@Pyhin1
1.95e-31	FFCP PHASE1:Hg19::chrX:19905661..19905699,-	p1@SH3KBP1
1.95e-31	FFCP PHASE2:Hg19::chrX:19905661..19905699,-	p1@SH3KBP1
2.0e-31	FFCP PHASE2:Hg19::chr17:16319083..16319126,+	p2@TRPV2
2.0e-31	FFCP PHASE1:Hg19::chr17:16319083..16319126,+	p2@TRPV2
3.22e-31	FFCP PHASE2:Hg19::chr2:192542577..192542595,-	p@chr2:192542577..192542595, -
3.22e-31	FFCP PHASE1:Hg19::chr2:192542577..192542595,-	p@chr2:192542577..192542595, -
3.83e-31	FFCP PHASE2:Hg19::chr3:15837528..15837578,-	p@chr3:15837528..15837578, -
3.83e-31	FFCP PHASE1:Hg19::chr3:15837528..15837578,-	p@chr3:15837528..15837578, -
6.88e-31	FFCP PHASE2:Mm9::chr3:60407657..60407673,+	p@chr3:60407657..60407673, +
6.88e-31	FFCP PHASE1:Mm9::chr3:60407657..60407673,+	p@chr3:60407657..60407673, +
7.86e-31	FFCP PHASE2:Hg19::chr4:80994619..80994633,-	p6@ANTXR2
7.86e-31	FFCP PHASE1:Hg19::chr4:80994619..80994633,-	p6@ANTXR2
9.65e-31	FFCP PHASE2:Hg19::chr17:16319065..16319082,+	p4@TRPV2
9.65e-31	FFCP PHASE1:Hg19::chr17:16319065..16319082,+	p4@TRPV2
1.37e-30	FFCP PHASE1:Hg19::chr13:100153737..100153785,+	p1@TM9SF2
1.37e-30	FFCP PHASE2:Hg19::chr13:100153737..100153785,+	p1@TM9SF2
1.4e-30	FFCP PHASE2:Hg19::chr2:182322344..182322359,+	p6@ITGA4
1.4e-30	FFCP PHASE1:Hg19::chr2:182322344..182322359,+	p6@ITGA4
1.69e-30	FFCP PHASE1:Hg19::chr10:70847852..70847873,+	p1@SRGN
1.69e-30	FFCP PHASE2:Hg19::chr10:70847852..70847873,+	p1@SRGN
1.94e-30	FFCP PHASE1:Hg19::chr10:98480301..98480315,-	p3@PIK3AP1
1.94e-30	FFCP PHASE2:Hg19::chr10:98480301..98480315,-	p3@PIK3AP1
2.14e-30	FFCP PHASE1:Hg19::chr20:61584026..61584096,+	p1@SLC17A9
2.14e-30	FFCP PHASE2:Hg19::chr20:61584026..61584096,+	p1@SLC17A9
3.69e-30	FFCP PHASE2:Hg19::chr5:42950949..42951013,+	p@chr5:42950949..42951013, +
3.69e-30	FFCP PHASE1:Hg19::chr5:42950949..42951013,+	p@chr5:42950949..42951013, +
3.76e-30	FFCP PHASE2:Hg19::chr11:67806467..67806527,+	p1@TCIRG1
3.76e-30	FFCP PHASE1:Hg19::chr11:67806467..67806527,+	p1@TCIRG1
4.34e-30	FFCP PHASE1:Hg19::chr13:41593392..41593403,-	p7@ELF1
4.34e-30	FFCP PHASE2:Hg19::chr13:41593392..41593403,-	p7@ELF1
4.67e-30	FFCP PHASE2:Mm9::chr17:84587077..84587097,-	p4@Zfp36l2
4.67e-30	FFCP PHASE1:Mm9::chr17:84587077..84587097,-	p4@Zfp36l2
6.1e-30	FFCP PHASE2:Hg19::chr18:3449527..3449582,+	p6@TGIF1
6.1e-30	FFCP PHASE1:Hg19::chr18:3449527..3449582,+	p6@TGIF1
1.63e-29	FFCP PHASE2:Hg19::chr5:169724839..169724855,-	p3@LCP2
1.63e-29	FFCP PHASE1:Hg19::chr5:169724839..169724855,-	p3@LCP2

Showing 1 to 100 of 100 entries